ABBN.SW: $86.32 ▲ 0.22 (0.26%)ASML.AS: $1,564.40 ▲ 3.60 (0.23%)ENR.DE: $160.56 ▼ -1.94 (-1.19%)GLEN.L: $536.50 ▲ 1.20 (0.22%)IFX.DE: $81.36 ▲ 0.80 (0.99%)NOKIA.HE: $12.12 ▲ 0.12 (0.96%)RIO.L: $7,290.00 ▲ 26.00 (0.36%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

electroCore, Inc.

ECOR - NASDAQ

Identifiants & Marche

Ticker ECOR
ISIN US28531P2020
CIK 0001560258
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.